Replimune Group Inc. REPL
$8.71
▲ +3.02% 24H
About
Replimune Group Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing oncolytic immunotherapies for cancer treatment. Its proprietary product candidates harness oncolytic viruses to selectively replicate in and destroy tumor cells while activating the patient's immune system against…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees479
TickerREPL
Statistics
Market Cap$693.2M
Revenue (TTM)$0
Net Income-$247.3M
Net Margin—
EPS$-3.07
P/E-2.89
P/S—
P/B3.36
EV/EBITDA-1.63
ROE-90.9%
Dividend Yield—
Price$8.71
Data: Twelve Data · Revenue = mcap / P/S